Daniel C.-H. Lin

West Virginia University — United States

Medicine · Health Sciences

23h-index3.0kcitations36works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(14), Receptor Mechanisms and Signaling(13), Pancreatic function and diabetes(8), Neurotransmitter Receptor Influence on Behavior(7), Neuropeptides and Animal Physiology(5)

Publications36 total

Inhalation of Ultrafine Carbon Black-Induced Mitochondrial Dysfunction in Mouse Heart Through Changes in Acetylation
Cells·2025Open Access
[Safety and efficacy of aspheric phakic IOL implantation in myopia: short-term clinical results].
PubMed·2025
Sex‐dependent effects of a high‐fat diet‐induced obesity model on cerebrovascular health and brain metabolism
Experimental Physiology·2025Open Access
Investigating the potential role of post-translational modification in regulating mitochondrial dysfunction in high-fat diet brain
Free Radical Biology and Medicine·2024
THU-198 In vitro and in vivo pharmacological characterization of human PNPLA3-targeting short interfering RNA molecules for the treatment of metabolic dysfunction-associated steatohepatitis
Journal of Hepatology·2024
A scalable organoid model of human autosomal dominant polycystic kidney disease for disease mechanism and drug discovery
Cell stem cell·2022· 121 citedOpen Access
Structural basis for pharmacological modulation of the TRPC6 channel
eLife·2020· 113 citedOpen Access
Author response: Structural basis for pharmacological modulation of the TRPC6 channel
2020· 1 citedOpen Access
Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates
ACS Medicinal Chemistry Letters·2018· 14 citedOpen Access
Discovery of the imidazole-derived GPR40 agonist AM-3189
Bioorganic & Medicinal Chemistry Letters·2015· 18 citedOpen Access
Optimization of GPR40 Agonists for Type 2 Diabetes
ACS Medicinal Chemistry Letters·2014· 43 citedOpen Access
Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists
ACS Medicinal Chemistry Letters·2014· 24 citedOpen Access
Modulating GPR40: therapeutic promise and potential in diabetes
Drug Discovery Today·2013· 56 cited
Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles
ACS Medicinal Chemistry Letters·2013· 81 citedOpen Access
Aminopyrazole–Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies
ACS Medicinal Chemistry Letters·2013· 26 citedOpen Access
Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1
Molecular and Cellular Endocrinology·2013· 88 cited
A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents
PLoS ONE·2012· 136 citedOpen Access
Evaluating insulin secretagogues in a humanized mouse model with functional human islets
Metabolism·2012· 15 cited
Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist
ACS Medicinal Chemistry Letters·2012· 89 citedOpen Access
Identification and Pharmacological Characterization of Multiple Allosteric Binding Sites on the Free Fatty Acid 1 Receptor
Molecular Pharmacology·2012· 119 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Jonathan B. Houze(13), Jian Luo(12), Jane Zhang(11), Gayathri Swaminath(9), Run Zhuang(9), Paul J. Dransfield(8), Yingcai Wang(8), Sean P. Brown(7), Liusheng Zhu(7), Jiwen Liu(7), Julio C. Medina(7), Marc Vimolratana(6), Frank Li(6), Kathy Nguyen(5), Xian‐Yun Jiao(5), Qi Guo(4), Thanhvien Tran(4), Simon Wong(4), George Tonn(4), Simon Wong(4)